Capacidad innovativa en México para la producción de medicamentos antirretrovirales.

Abstract

Mexico is a country in which the pharmaceutical market is considered within the 10 largest in the world, being a Latin American leader with Brazil and Argentina. The production of 86% of the drugs with which the Mexicans fight disease is held by the pharmaceutical industry in the country, while only 14% are imported. But in the category of antiretrovirals, the circumstances have not been as favorable. In 2008 the elimination of the plant requirement, to allow foreign pharmaceutical companies to introduce and sell generic drugs in Mexico, helped to reduce the cost of antiretrovirals, but the decision has an impact only on five of the drugs against HIV who have already lost patent protection. The other 27 commonly used antiretrovirals still have the rights of industrial property protection. This research is aimed to the study of the national innovative capacity to produce antiretrovirals, since the World Health Organization estimates that there are in Mexico approximately 220,000 people living with HIV/AIDS, which is not only an alarming number for the health sector, but also for the social environment.